FLT PET/CT in Measuring Response in Patients With Previously Untreated Acute Myeloid Leukemia

Summary

This phase II trial studies fluorothymidine F 18 (FLT) positron emission tomography (PET)/computed tomography (CT) in measuring response in patients with previously untreated acute myeloid leukemia. FLT is a radioactive substance that may "light up" where cancer is in the body. FLT is injected into the blood and builds up in cells that are dividing, including cancer cells. Diagnostic procedures, such as PET/CT, may help measure a patient's response to earlier treatment.

Timeline

Start

2016-04-20

Primary completion

2023-12-31

Completion

2027-02-13

Drugs

Indications